NCT03710707View on ClinicalTrials.gov

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

December 6, 2019

Study Completion Date

December 6, 2019

Conditions
Parkinson Disease
Interventions
DRUG

DNL201

Oral repeating dose

DRUG

Placebo

Oral repeating dose

Trial Locations (7)

19104

Clinical Site(s), Philadelphia

32806

Clinical Site(s), Orlando

33143

Clinical Site(s), Miami

48334

Clinical Site(s), Farmington Hills

80045

Clinical Site(s), Aurora

90808

Clinical Site(s), Long Beach

99202

Clinical Site(s), Spokane

Sponsors
All Listed Sponsors
lead

Denali Therapeutics Inc.

INDUSTRY